A carefully maintained longitudinal, observational study of patients treated with telaprevir and boceprevir within academic and real-world community practices can rapidly inform strategies:

  • For better management of populations both represented and underrepresented in Ph III clinical trials
  • To identify educational gaps relative to treatment guidelines and management of adverse events
  • To develop a core for translational studies
  • To implement a rapid clinical trials network for novel studies